 EDISON, N.J., May 06, 2021 GLOBE NEWSWIRE -- Hepion Pharmaceuticals, Inc. NASDAQ:HEPA, a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis NASH, today announced that it has completed recruitment for its Phase 2a AMBITION clinical trial, with all NASH patients in the 225 mg CRV431 dosing cohort now enrolled. 